1. Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing
- Author
-
Rachel F. Dear, James French, Tram B. Doan, Michelle White, Elisabeth N. Elder, Jeremy Hsu, Stephen B. Fox, Rina Hui, Meagan Brennan, Paul R. Harnett, G. Bruce Mann, Elgene Lim, Farid Meybodi, Masrura Kabir, Nirmala Pathmanathan, Nicholas Wilcken, Phuong Dinh, Kirsty Stuart, Tim Wang, Verity Ahern, and J. Dinny Graham
- Subjects
Cancer Research ,medicine.medical_specialty ,business.industry ,Logistic regression ,medicine.disease ,Breast cancer ,Oncology ,Internal medicine ,Progesterone receptor ,Cohort ,Adjuvant therapy ,Medicine ,Treatment decision making ,Intermediate Grade ,business ,Early breast cancer - Abstract
PURPOSE Genomic tests improve accuracy of risk prediction for early breast cancers but these are expensive. This study evaluated the clinical utility of EndoPredict®, in terms of impact on adjuvant therapy recommendations and identification of parameters to guide selective application. METHODS Patients with ER-positive, HER2-negative, and early-stage invasive breast cancer were tested with EndoPredict®. Two cohorts were recruited: one consecutively and another at clinical team discretion. Systemic treatment recommendations were recorded before and after EndoPredict® results were revealed to the multidisciplinary team. RESULTS 233 patients were recruited across five sites: 123 consecutive and 110 at clinical team discretion. In the consecutive cohort 50.6% (62/123) cases were classified high risk of recurrence by EndoPredict®, compared with 62.7% (69/110) in the selective cohort. A change in treatment recommendation was significantly more likely (p
- Published
- 2021
- Full Text
- View/download PDF